Genetic testing informs risk stratification in dilated cardiomyopathy (DCM), yet likely pathogenic/pathogenic (LP/P) variants are identified in only one-third of patients. Gene-elusive DCM may confer a lower risk of adverse clinical events than genotype-positive disease, but remains poorly characterised. Left bun...
D. Cannie, A. Bakalakos, P. Syrris et al.· European Heart Journal· 0 citations
The risk of malignant ventricular arrhythmia (MVA) and end-stage heart failure (ESHF) in dilated cardiomyopathy (DCM) may vary by genotype.1 Comparative analyses remain limited.
To compare clinical outcomes and risk predictors across genotypes.
Carriers of pathogenic/likely pathogenic variants in DC...
D. Cannie, A. Bakalakos, P. Syrris et al.· European Heart Journal· 0 citations
In this large HCM cohort, variant re-evaluation resulted in a modest but clinically relevant reclassification of genetic variants, consistent with consolidation of locus-specific evidence and important given their association with adverse outcomes, despite modest hypertrophy.
A. Bakalakos, R. Lorca, A. Protonotarios et al.· European Journal of Human Ge...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.